| Scrip Code | 539523 |
|---|---|
| NSE Symbol | ALKEM |
| MSEI Symbol | NOTLISTED |
| ISIN | INE540L01014 |
| Name of company | ALKEM LABORATORIES LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2026 |
| Date of end of financial year | 31-03-2027 |
| Date of board meeting when results were approved | 14-08-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 21-07-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | First quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |
| Segment Reporting | Single segment |
| Description of single segment | The Company is exclusively engaged in pharmaceutical business |
| Start date and time of board meeting | 14-08-2026 11:00:00 |
| End date and time of board meeting | 14-08-2026 13:40:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | No |
| No. of times funds raised during the quarter | |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | Yes |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| 1 | Income | ||
| Revenue from operations | 2,66,773.00 | 2,66,773.00 | |
| Other income | 13,662.00 | 13,662.00 | |
| Total income | 2,80,435.00 | 2,80,435.00 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 67,288.00 | 67,288.00 |
| (b) | Purchases of stock-in-trade | 14,666.00 | 14,666.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (6,349.00) | (6,349.00) |
| (d) | Employee benefit expense | 54,747.00 | 54,747.00 |
| (e) | Finance costs | 1,752.00 | 1,752.00 |
| (f) | Depreciation, depletion and amortisation expense | 5,722.00 | 5,722.00 |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 62,767.00 | 62,767.00 |
| Total other expenses | 62,767.00 | 62,767.00 | |
| Total expenses | 2,00,593.00 | 2,00,593.00 | |
| 3 | Total profit before exceptional items and tax | 79,842.00 | 79,842.00 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 79,842.00 | 79,842.00 |
| 6 | Tax expense | ||
| 7 | Current tax | 20,774.00 | 20,774.00 |
| 8 | Deferred tax | 2,070.00 | 2,070.00 |
| 9 | Total tax expenses | 22,844.00 | 22,844.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 56,998.00 | 56,998.00 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 56,998.00 | 56,998.00 |
| 17 | Other comprehensive income net of taxes | (256.00) | (256.00) |
| 18 | Total Comprehensive Income for the period | 56,742.00 | 56,742.00 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 2,391.00 | 2,391.00 | |
| Face value of equity share capital | 2 | 2 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 47.67 | 47.67 | |
| Diluted earnings (loss) per share from continuing operations | 47.67 | 47.67 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 47.67 | 47.67 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 47.67 | 47.67 | |
| 24 | Debt equity ratio | 0 | 0 |
| 25 | Debt service coverage ratio | 0 | 0 |
| 26 | Interest service coverage ratio | 0 | 0 |
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | 1) The above standalone financial results are prepared in accordance with the lndian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). 2) The above standalone financial results of the Company were reviewed and recommended by the Audit Committee on 13 August 2026 and subsequently approved by the Board of Directors at its meeting held on 14 August 2026. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2026. The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year. 3) The Board of Directors of the Company at their meeting held on 10 December 2024 had approved the transfer of Generic Business Undertaking to Alkem Wellness Limited, a wholly owned subsidiary of the Company as a going concern, on a slump sale basis. The Company has executed a Business Transfer Agreement (BTA), effective 01 October 2025, and transferred its Generic business to Alkem Wellness Limited. During the earlier periods, the transfer of the Generic Business had been disclosed as discontinued operations in accordance with Ind AS 105 Non - current Assets Held for Sale and Discontinued Operations. The figures for the previous periods have been restated to give effect to the presentation requirement of Ind AS 105 Non - current Assets Held for Sale and Discontinued Operations. Key financial information of Discontinued Operations: Particulars: Quarter ended June 30, 2026: Total income: NIL Total expenses: NIL Profit before tax: NIL Total tax expense: NIL Net profit for the period after tax: NIL Quarter ended March 31, 2026 Total income: NIL Total expenses: NIL Profit before tax: NIL Total tax expense: NIL Net profit for the period after tax: NIL YTD June 30, 2025 Total income: 3,558.2 Total expenses: 3,037.2 Profit before tax: 521.0 Total tax expense: 182.0 Net profit for the period after tax: 339.0 Year end March 31, 2026 Total income: 9,181.0 Total expenses: 7,690.5 Profit before tax: 1,490.5 Total tax expense: 520.8 Net profit for the period after tax: 969.7 4) Exceptional items include: 1) During the quarter and year ended 31 March 2026 year, the Company reviewed its investments in real estate; where recoverability was subject to uncertainties. Accordingly, management has reassessed the carrying value of such investments and recognised a provision for impairment amounting to Rs. 747 million, which has been disclosed as an exceptional item for the quarter and year ended March 31, 2026. 2) During the previous year, pursuant to the notification and subsequent finalisation of the Central Rules under the Labour Codes by the Government of India, the Company assessed the financial impact of the revised regulatory framework, including the Code on Social Security, 2020, based on detailed evaluation of the notified provisions, professional advice, and actuarial valuation. Based on this assessment, the Company recognised an estimated liability towards gratuity and leave encashment for past service cost aggregating to Rs. 445.1 million in the quarter ended 31 March 2026 and of Rs. 826.8 million for the year ended 31 March 2026. The total impact has been disclosed as an exceptional item in the financial results. 3) The Company sold its Indore manufacturing facility in the quarter ended 30 June 2025. The resulting gain (arising out of reversal of impairment loss) amounting to Rs.142.9 million had been classified and disclosed as an exceptional item in the results for the quarter ended 30 June 2025 and year ended 31 March 2026. 5) During the quarter and year ended 31 March 2026, pursuant to the amendments introduced under the Finance Act, 2026, interalia allowing set off of available MAT credit under new tax regime (Section 115BAA of the Income-tax Act, 1961), the Company has decided to opt for the new tax regime from financial year 2026 – 27. Consequently, deferred tax had been recognised at the substantially enacted rate as at 31 March 2026. Subsequently in the current quarter tax expense has been recognized based on the enacted tax rates applicable under the new regime. 6) The Company operates in one reportable business segment i.e. Pharmaceuticals, accordingly no separate disclosure of segment information has been made. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-04-2026 | 01-04-2026 | |||||
| Date of end of reporting period | 30-06-2026 | 30-06-2026 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | tems that will not be reclassified to profit or loss | (342.00) | (342.00) |
| Total Amount of items that will not be reclassified to profit and loss | (342.00) | ||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | (86.00) | (86.00) |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 |
| 5 | Total Other comprehensive income | (256.00) | (256.00) |
| Sr. No. | Particulars | Amount | Remarks |
| 1. | Loans / revolving facilities like cash credit from banks / financial institutions | ||
| A | Total amount outstanding as on date | 0.00 | |
|---|---|---|---|
| B | Of the total amount outstanding, amount of default as on date | 0.00 | |
| 2. | Unlisted debt securities i.e. NCDs and NCRPS | ||
| A | Total amount outstanding as on date | 0.00 | |
| B | Of the total amount outstanding, amount of default as on date | 0.00 | |
| 3. | Total financial indebtedness of the listed entity including short-term and long-term debt | 0.00 | |